Stocktoria
Dare Bioscience, Inc. DARE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-04-10
Dare Bioscience, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $9,784 | $2.8M | $10.0M | $0 | — | — | — | — | $766,000 |
| R&D expense | $5.5M | $14.3M | $21.5M | $30.0M | $30.6M | $20.8M | $8.5M | $6.4M | $984,749 | $72,666 |
| SG&A expense | $8.8M | $9.2M | — | — | — | — | — | — | — | — |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M | -$27.4M | -$14.3M | -$16.9M | -$11.2M | -$630,591 |
| Interest expense | — | — | — | — | — | — | — | — | $322,629 | $42,096 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3,200 | $0 | — |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | -$38.7M | -$27.4M | -$14.3M | -$16.7M | -$11.5M | -$672,687 |
| EPS (diluted) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 | $-0.91 | — | — | — | — |
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M | -$25.2M | -$13.3M | -$10.3M | -$2.5M | -$372,299 |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M | -$25.3M | -$13.3M | -$10.3M | -$2.5M | -$907,299 |
| Cash & equivalents | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M | $4.7M | $4.8M | $6.8M | $7.6M | $44,614 |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M | $7.6M | $7.4M | $7.8M | $14.3M | $44,614 |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M | $8.7M | $7.0M | $1.1M | $967,045 | $755,235 |
| Shareholders' equity | $2.8M | -$6.0M | -$5.0M | $11.1M | $38.8M | -$1.2M | $440,826 | $6.7M | $13.3M | -$710,621 |
Growth · year-over-year · Revenue CAGR 6.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +10429.4% | -99.7% | -71.9% | — | — | — | — | — | — | — |
| Free cash flow growth | -309.9% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.